Xenon Pharmaceuticals Changes Auditor to Ernst & Young LLP
Ticker: XENE · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Xenon Pharma swapped auditors from PwC to EY on March 3rd.
AI Summary
On March 3, 2025, Xenon Pharmaceuticals Inc. filed an 8-K report to disclose a change in its certifying accountant. The company has appointed Ernst & Young LLP as its new independent registered public accounting firm, replacing PricewaterhouseCoopers LLP.
Why It Matters
A change in a company's auditor can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting.
Risk Assessment
Risk Level: low — This filing solely concerns a change in the company's auditor, which is a routine administrative event.
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Registrant
- Ernst & Young LLP (company) — New independent registered public accounting firm
- PricewaterhouseCoopers LLP (company) — Former independent registered public accounting firm
- March 3, 2025 (date) — Date of earliest event reported
FAQ
When was the change in Xenon Pharmaceuticals Inc.'s certifying accountant effective?
The change in certifying accountant was effective as of March 3, 2025.
Who is Xenon Pharmaceuticals Inc.'s new independent registered public accounting firm?
Xenon Pharmaceuticals Inc. has appointed Ernst & Young LLP as its new independent registered public accounting firm.
Who was Xenon Pharmaceuticals Inc.'s previous independent registered public accounting firm?
Xenon Pharmaceuticals Inc.'s previous independent registered public accounting firm was PricewaterhouseCoopers LLP.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a change in Xenon Pharmaceuticals Inc.'s certifying accountant.
What is Xenon Pharmaceuticals Inc.'s principal executive office address?
Xenon Pharmaceuticals Inc.'s principal executive office is located at 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding Xenon Pharmaceuticals Inc. (XENE).